191 related articles for article (PubMed ID: 35113907)
1. Tolerability of nintedanib in the elderly with idiopathic pulmonary fibrosis: A single-center retrospective study.
Komatsu M; Yamamoto H; Ichiyama T; Kawakami S; Uehara T; Yoshikawa Y; Kitaguchi Y; Ushiki A; Yasuo M; Hanaoka M
PLoS One; 2022; 17(2):e0262795. PubMed ID: 35113907
[TBL] [Abstract][Full Text] [Related]
2. A retrospective study of the tolerability of nintedanib for severe idiopathic pulmonary fibrosis in the real world.
Nakamura M; Okamoto M; Fujimoto K; Ebata T; Tominaga M; Nouno T; Zaizen Y; Kaieda S; Tsuda T; Kawayama T; Hoshino T
Ann Transl Med; 2019 Jun; 7(12):262. PubMed ID: 31355229
[TBL] [Abstract][Full Text] [Related]
3. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
4. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
5. Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Brunnemer E; Wälscher J; Tenenbaum S; Hausmanns J; Schulze K; Seiter M; Heussel CP; Warth A; Herth FJF; Kreuter M
Respiration; 2018; 95(5):301-309. PubMed ID: 29490307
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis.
Uchida Y; Ikeda S; Sekine A; Katano T; Tabata E; Oda T; Okuda R; Kitamura H; Baba T; Komatsu S; Ogura T
Respir Investig; 2021 Jan; 59(1):99-105. PubMed ID: 32891571
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil.
Pereira CAC; Baddini-Martinez JA; Baldi BG; Jezler SFO; Rubin AS; Alves RLR; Zonzin GA; Quaresma M; Trampisch M; Rabahi MF
J Bras Pneumol; 2019 Sep; 45(5):e20180414. PubMed ID: 31531619
[TBL] [Abstract][Full Text] [Related]
8. Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis.
Bonella F; Kreuter M; Hagmeyer L; Neurohr C; Keller C; Kohlhaeufl MJ; Müller-Quernheim J; Milger K; Prasse A;
Respiration; 2016; 92(2):98-106. PubMed ID: 27544537
[TBL] [Abstract][Full Text] [Related]
9. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Magnusson MO; Freiwald M
Respir Med; 2021; 180():106369. PubMed ID: 33798871
[TBL] [Abstract][Full Text] [Related]
10. Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study.
Abe M; Tsushima K; Sakayori M; Suzuki K; Ikari J; Terada J; Tatsumi K
Drug Des Devel Ther; 2018; 12():3369-3375. PubMed ID: 30349191
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities.
Glaspole I; Bonella F; Bargagli E; Glassberg MK; Caro F; Stansen W; Quaresma M; Orsatti L; Bendstrup E
Respir Res; 2021 Apr; 22(1):125. PubMed ID: 33902584
[TBL] [Abstract][Full Text] [Related]
12. Lung function outcomes in the INPULSIS
Brown KK; Flaherty KR; Cottin V; Raghu G; Inoue Y; Azuma A; Huggins JT; Richeldi L; Stowasser S; Stansen W; Schlenker-Herceg R; Maher TM; Wells AU
Respir Med; 2019 Jan; 146():42-48. PubMed ID: 30665517
[TBL] [Abstract][Full Text] [Related]
13. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
Ikeda S; Sekine A; Baba T; Katano T; Tabata E; Shintani R; Sadoyama S; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
BMC Pulm Med; 2019 Apr; 19(1):78. PubMed ID: 30975118
[TBL] [Abstract][Full Text] [Related]
14. Clinical Significance of Continuable Treatment with Nintedanib Over 12 Months for Idiopathic Pulmonary Fibrosis in a Real-World Setting.
Kato M; Sasaki S; Tateyama M; Arai Y; Motomura H; Sumiyoshi I; Ochi Y; Watanabe J; Ihara H; Togo S; Takahashi K
Drug Des Devel Ther; 2021; 15():223-230. PubMed ID: 33500614
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.
Kreuter M; Wuyts WA; Wijsenbeek M; Bajwah S; Maher TM; Stowasser S; Male N; Stansen W; Schoof N; Orsatti L; Swigris J
Respir Res; 2020 Jan; 21(1):36. PubMed ID: 32000772
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis.
Richeldi L; Kolb M; Jouneau S; Wuyts WA; Schinzel B; Stowasser S; Quaresma M; Raghu G
BMC Pulm Med; 2020 Jan; 20(1):3. PubMed ID: 31914963
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis.
Yoon HY; Park S; Kim DS; Song JW
Respir Res; 2018 Oct; 19(1):203. PubMed ID: 30340638
[TBL] [Abstract][Full Text] [Related]
18. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
[TBL] [Abstract][Full Text] [Related]
19. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Sarr C; Freiwald M
BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
[TBL] [Abstract][Full Text] [Related]
20. A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis.
Harari S; Caminati A; Poletti V; Confalonieri M; Gasparini S; Lacedonia D; Luppi F; Pesci A; Sebastiani A; Spagnolo P; Vancheri C; Balestro E; Bonifazi M; Cerri S; De Giacomi F; Della Porta R; Foschino Barbaro MP; Fui A; Pasquinelli P; Rosso R; Tomassetti S; Specchia C; Rottoli P;
Respiration; 2018; 95(6):433-440. PubMed ID: 29587263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
